Anuh Pharma Posts Strong Revenue Growth in FY26 Amid Profit Pressure

Anuh Pharma's operating revenue for FY26 reached ₹771.66 Cr, a significant 16.65% increase from ₹661.51 Cr in FY25. The fourth quarter of FY26 saw revenue at ₹202.12 Cr, up 2.50% sequentially from ₹197.18 Cr in the prior quarter. Exports contributed approximately 46% of the total revenue for the fiscal year.

Reader Takeaway: Robust revenue growth and successful regulatory approvals contrast with declining profitability and margin pressure.

What just happened

Anuh Pharma Ltd. announced its financial results for the fiscal year ending March 31, 2026 (FY26). The company reported a 16.65% year-on-year increase in operating revenue to ₹771.66 Cr. However, the Profit After Tax (PAT) saw a 13.32% decrease to ₹41.05 Cr for the full year. The fourth quarter of FY26 also reported a sequential dip in PAT, down 13.16% to ₹11.68 Cr, despite a 2.50% rise in revenue.

Why this matters

The strong revenue growth indicates expanding market reach and demand for Anuh Pharma's products, particularly from exports to regulated markets. The successful completion of USFDA and EU GMP inspections bolsters the company's credibility and market access. However, the decline in PAT, coupled with lower EBITDA margins year-on-year and sequentially, raises concerns about cost management and pricing power, which could impact shareholder returns despite topline expansion.

The backstory

In the previous fiscal year (FY25), Anuh Pharma had reported operating revenue of ₹661.51 Cr and PAT of ₹47.35 Cr. The company has been focusing on expanding its high-value product portfolio and increasing its presence in regulated markets. The development of new products like Vonoprazon Fumarate, Pretomanid, and Edoxaban Tosylate is part of its strategy to drive future growth.

What changes now

With the successful regulatory clearances and a guided annual growth rate of 15-20%, Anuh Pharma is positioned for continued expansion. The company will likely focus on leveraging its compliance achievements to boost sales in key international markets. Investors will be keenly observing the company's ability to manage its costs and improve margins to convert revenue growth into improved profitability.

Risks to watch

Key risks include potential margin erosion due to increased competition or raw material costs, challenges in translating new product development into significant revenue, and fluctuations in international market demand. The company needs to demonstrate a consistent ability to maintain and improve profitability alongside revenue growth.

Peer comparison

While specific peer financial data for FY26 is not detailed here, the pharmaceutical sector, especially API manufacturers, often faces margin pressures due to intense competition and regulatory compliance costs. Companies with strong footholds in regulated markets like the US and Europe typically command better valuations, provided they can maintain healthy profitability.

Context metrics

• FY26 Operating Revenue: ₹771.66 Cr (vs. ₹661.51 Cr in FY25, +16.65% YoY)
• FY26 PAT: ₹41.05 Cr (vs. ₹47.35 Cr in FY25, -13.32% YoY)
• Q4 FY26 Operating Revenue: ₹202.12 Cr (vs. ₹197.18 Cr in Q3 FY26, +2.50% QoQ)
• Q4 FY26 PAT: ₹11.68 Cr (vs. ₹13.45 Cr in Q3 FY26, -13.16% QoQ)
• USFDA and EU GMP inspections: Successfully completed

What to track next

Investors should monitor Anuh Pharma's quarterly results for signs of margin improvement, the progress of new product launches, and continued success in expanding its footprint in regulated markets. Management's ability to meet its 15-20% annual growth guidance while improving profitability will be crucial.